Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3032-3037

  Bocci, Guido ^a   Danesi, Romano ^a   Di Paolo, Antonello ^a   Innocenti, Federico ^a   Allegrini, Giacomo ^b   Falcone, Alfredo ^b   Melosi, Alessandro ^c   Battistoni, Mario ^c   Barsanti, Gemma ^c   Conte, Pier Franco ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c General Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXIDOREDUCTASES;

EID: 0033870677     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Machover, D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer (Phila.), 80: 1179-1187, 1997.
2. Peters, G. J. Antimetabolites. In: M. Peckam, H. M. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, pp. 524-552. London: Oxford University Press, 1995.
3. Diasio, R. B., and Harris, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
4. Schaaf, L. J., Dobbs, B. R., Edwards, I. R., and Perrier, D. G. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur. J. Clin. Pharmacol., 32: 411-418, 1987.
5. van Groeningen, C. J., Pinedo, H. M., Heddes, J., Kok, R. M., de Jong, A. P. J. M., Wattel, E., Peters, G. J., and Lankelma, J. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res., 48: 6956-6961, 1988.
6. Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
7. Van Kuilenburg, A. B., Van Lenthe, H., Wanders, R. J., and Van Gennip, A. H. Subcellular localization of dihydropyrimidine dehydrogenase. Biol. Chem. Hoppe Seyler, 378: 1047-1053, 1997.
8. McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., Koruth, M., and Cassidy, J. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer, 77: 461-465, 1998.
9. Gonzalez, F. J., and Fernandez-Salguero, P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci., 16: 325-327, 1995.
10. Diasio, R. B., and Lu, Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J. Clin. Oncol., 12: 2239-2242, 1994.
11. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Investig., 81: 47-51, 1988.
12. Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., Canney, P., Fernandez-Salguero, P., Gonzalez, F. J., Cassidy, J., and McLeod, H. L. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. J. Cancer, 77: 497-500, 1998.
13. Vrecken, P., Van Kuilenburg, A. B., Meinsma, R., and Van Gennip, A. H. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum. Genet., 101: 333-338, 1997.
14. Milano, G., and Etienne, M. C. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits. Ther. Drug. Monit., 18: 335-340, 1996.
15. Machover, D., Goldschmidt, E., Chollet, P., Metzger, G., Zittoun, J., Marquet, J., Vandenbulcke, J. M., Misset, J. L., Schwarzenberg, L., and Fourtillan, J. B. Treatment of advanced colorectal and gastric carcinoma with 5-fluorouracil and high-dose folinic acid. J. Clin. Oncol., 4: 685-696, 1986.
16. Danesi, R., Falcone, A., Innocenti, F., Bocci, G., Di Paolo, A., Allegrini, G., Conte, P. F., and Del Tacca, M. Chromatographic analysis of 5-fluoro-5,6-dihydrouracil: application to study 5-FU catabolism and dihydropyrimidine dehydrogenase activity in patients. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 822, 1997.
17. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renee, N., Schneider, M., Demard, F., and Milano, G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12: 2248-2253, 1994.
18. Gibaldi, M., and Perrier, D. Pharmacokinetics. New York: Marcel Dekker, Inc., 1982.
19. Collins, J. M., Dedrick, R. L., King, F. G., Speyer, J. L., and Myers, C. E. Nonlinear pharmacokinetic models of 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin. Pharmacol. Ther., 28: 235-246, 1980.
20. Stephan, F., Etienne, M. C., Wallays, C., Milano, G., and Clerque, F. Depressed hepatic dihydrogenase activity and fluorouracil-related toxicities. Am. I. Med., 99: 685-688, 1995.
21. Van Kuilenburg, A. B. P., Van Lenthe H., Blom, M. J., Mul, E. P. J., and Van Gennip, A. H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br. J. Cancer, 79: 620-626, 1999.
22. Coustere, C., Mentre, F., Sommadossi, J. P., Diasio, R. B., and Steimer, J. L. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother. Pharmacol., 28: 123-129, 1991.
23. Gamelin, E., Boisdron-Celle, M., Guerin-Meyer, V., Delva, R., Lortholary, A., Genevieve, F., Larra, F., Ifrah, N., and Robert, J. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol., 17: 1105-1110, 1999.
24. Grem, J. L., Yee, L. K., Venzon, D. J., Takimoto, C. H., and Allegra, C. J. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother. Pharmacol., 40: 117-125, 1997.
25. Wei, X., McLeod, H. L., McMurrough, J., Gonzalez, F. J., and Fernandez-Salguero, P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Investig., 98: 610-615, 1996.
26. Johnson, M. R., Yan, J., Shao, L., Albin, N., and Diasio, R. B. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J. Chromatogr. B Biomed. Sci. Appl., 696: 183-191, 1997.